These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 11144460)

  • 41. Assuring bioavailability of fixed-dose combinations of anti-tuberculosis medications. A joint statement of the International Union Against Tuberculosis and Lung Diseases and the World Health Organization.
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S282-3. PubMed ID: 10593704
    [No Abstract]   [Full Text] [Related]  

  • 42. Sample size calculation for the Power Model for dose proportionality studies.
    Sethuraman VS; Leonov S; Squassante L; Mitchell TR; Hale MD
    Pharm Stat; 2007; 6(1):35-41. PubMed ID: 17323313
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rifampicin serum levels in childhood tuberculosis.
    Thee S; Detjen A; Wahn U; Magdorf K
    Int J Tuberc Lung Dis; 2009 Sep; 13(9):1106-11. PubMed ID: 19723399
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of the bioequivalence of zidovudine 100 mg capsules in healthy Thai male volunteers.
    Chompootaweep S; Poonsrisawat J; Xumseang P
    J Med Assoc Thai; 2006 Sep; 89 Suppl 3():S79-85. PubMed ID: 17722305
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An adjusted two one-sided t-test for the assessment of bioequivalence with multiple doses.
    Wang W; Hsuan F; Chow SC
    J Biopharm Stat; 1997 Mar; 7(1):157-70. PubMed ID: 9056595
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bioequivalence trials of rifampicin containing formulations: extrinsic and intrinsic factors in the absorption of rifampicin.
    Agrawal S; Singh I; Kaur KJ; Bhade S; Kaul CL; Panchagnula R
    Pharmacol Res; 2004 Sep; 50(3):317-27. PubMed ID: 15225676
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase I pharmacokinetic study of a new 3-azinomethyl-rifamycin (rifametane) as compared to rifampicin.
    Potkar C; Gogtay N; Gokhale P; Kshirsagar NA; Ajay S; Cooverji ND; Bruzzese T
    Chemotherapy; 1999; 45(3):147-53. PubMed ID: 10224335
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bioequivalence evaluation of two brands of amoxicillin/clavulanic acid 250/125 mg combination tablets in healthy human volunteers: use of replicate design approach.
    Idkaidek NM; Al-Ghazawi A; Najib NM
    Biopharm Drug Dispos; 2004 Dec; 25(9):367-72. PubMed ID: 15495146
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Implication of biopharmaceutics and pharmacokinetics of rifampicin in variable bioavailability from solid oral dosage forms.
    Agrawal S; Panchagnula R
    Biopharm Drug Dispos; 2005 Nov; 26(8):321-34. PubMed ID: 16059874
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Studies on a reverse micelle-lamellar phase transition based depot preparation of rifampicin.
    Uppadhyay AK; Omray LK; Khopade AJ; Jain NK
    Pharmazie; 1997 Dec; 52(12):961-2. PubMed ID: 9442561
    [No Abstract]   [Full Text] [Related]  

  • 51. Dissolution testing of marketed rifampicin containing fixed dose combination formulations using a new discriminative media: a post marketing retrospective study.
    Panchagnula R; Kumar Bajpai A; Agrawal S; Ashokraj Y
    Pharmazie; 2006 Oct; 61(10):851-4. PubMed ID: 17069424
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A pilot stability study on four-drug fixed-dose combination anti-tuberculosis products.
    Singh S; Mohan B
    Int J Tuberc Lung Dis; 2003 Mar; 7(3):298-303. PubMed ID: 12661847
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efforts of the WHO/IUATLD to solve the problem of poor bioavailability of rifampicin from FDC anti-tuberculosis products: is a change required in the direction of the approach in view of recent findings?
    Singh S
    Int J Tuberc Lung Dis; 2001 Sep; 5(9):880-2. PubMed ID: 11573905
    [No Abstract]   [Full Text] [Related]  

  • 54. Rifampicin mono-resistant Mycobacterium tuberculosis in Bujumbura, Burundi: results of a drug resistance survey.
    Sanders M; Van Deun A; Ntakirutimana D; Masabo JP; Rukundo J; Rigouts L; Fissette K; Portaelst F
    Int J Tuberc Lung Dis; 2006 Feb; 10(2):178-83. PubMed ID: 16499257
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bioequivalence evaluation of two brands of enalapril 20 mg tablets (Narapril and Renitec) in healthy human volunteers.
    Najib NM; Idkaidek N; Adel A; Admour I; Astigarraga RE; De Nucci G; Alam SM; Dham R; Qumaruzaman
    Biopharm Drug Dispos; 2003 Oct; 24(7):315-20. PubMed ID: 14520685
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bioequivalence evaluation of two brands of metformin 500 mg tablets (Dialon & Glucophage)--in healthy human volunteers.
    Najib N; Idkaidek N; Beshtawi M; Bader M; Admour I; Alam SM; Zaman Q; Dham R
    Biopharm Drug Dispos; 2002 Oct; 23(7):301-6. PubMed ID: 12355581
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis.
    Langdon G; Wilkins JJ; Smith PJ; McIlleron H
    Int J Tuberc Lung Dis; 2004 Jul; 8(7):862-7. PubMed ID: 15260278
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessing individual bioequivalence using the structural equation model.
    Carrasco JL; Jover L
    Stat Med; 2003 Mar; 22(6):901-12. PubMed ID: 12627408
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bioavailability of two licensed paediatric rifampicin suspensions: implications for quality control programmes.
    McIlleron H; Hundt H; Smythe W; Bekker A; Winckler J; van der Laan L; Smith P; Zar HJ; Hesseling AC; Maartens G; Wiesner L; van Rie A
    Int J Tuberc Lung Dis; 2016 Jul; 20(7):915-9. PubMed ID: 27287644
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bioequivalence of two levothyroxine tablet formulations without and with mathematical adjustment for basal thyroxine levels in healthy Argentinian volunteers: a single-dose, randomized, open-label, crossover study.
    Di Girolamo G; Keller GA; de Los Santos AR; Schere D; Gonzalez CD
    Clin Ther; 2008 Nov; 30(11):2015-23. PubMed ID: 19108789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.